A Single Centre, 5-Period, Randomized Study To Evaluate The Relative Bioavailability Of An Immediate Release Tablet Formulation And Prototype Bioenhanced Formulations Of GSK1325756 In Healthy Elderly Subjects During Suppression Of Gastric Acid Secretion.
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Danirixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- 26 Apr 2012 Actual patient numbers changed from 10 to 20 as reported by ClinicalTrials.gov.
- 13 Jan 2012 Actual patient numbers changed from 20 to 10 as reported by ClinicalTrials.gov.
- 13 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.